title: The safety of patient-controlled analgesia by proxy in pediatric oncology patients.
abstract: Between February 1999 and December 2003, we studied the use of patient-controlled analgesia (PCA) to control pain in 1011 children and young adults with cancer, by evaluating 4972 24-h periods of PCA usage, 576 of which involved PCA by proxy. Selection of patients for PCA by proxy was based on younger age group, neuromuscular limitation, expectation of repeated painful procedures, and terminal disease. We measured the incidence of respiratory and neurological complications related to the use of PCA. Major complications were observed during 70 of the 4972 24-h observations, with 28 of 4972, or 0.56%, involving respiratory complications, 35 of 4972, or 0.7%, involving neurological complications, and 7 of 4972 24-h observations, or 0.14%, involving both respiratory and neurological complications. In the PCA by proxy group two respiratory complications, two neurological complications and one mixed respiratory and neurological complication were observed [corrected] Reversal of opioid-related respiratory or neurological effects with naloxone was required in three instances, two in the standard PCA group and one in the PCA by proxy group. Recommendations to ensure continuing safety include careful patient selection, education of proxy users, appropriate documentation, and institutional guidelines.
authors.affiliation: Division of *Anesthesia and †Nursing Research and Patient Care Services, St. Jude Children's Research Hospital, Memphis, Tennessee.
authors.forename: Doralina L
authors.initials: DL
authors.lastname: Anghelescu
authors.forename: Laura L
authors.initials: LL
authors.lastname: Burgoyne
authors.forename: Linda L
authors.initials: LL
authors.lastname: Oakes
authors.forename: Debora A
authors.initials: DA
authors.lastname: Wallace
mesh_terms: D000293:Adolescent; D000328:Adult; D016058:Analgesia, Patient-Controlled / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D009369:Neoplasms / Q000503:physiopathology*; D019727:Proxy; D012119:Respiration / Q000187:drug effects